Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy

Abstract

A survival benefit could be potentially obtained with better PS by the combination of αβ T cell therapy, DC vaccine therapy, and chemotherapy at an early stage in pancreatic cancer.

Prognostic Factors for Colorectal Cancer Patients Treated With Combination of Immune-cell Therapy and First-line Chemotherapy: A Retrospective Study

“…Capecitabine, a prodrug of 5-FU, has also been reported to reverse tumor escape by inhibiting MDSCs more effectively than 5-FU could (29). Thus, these findings suggest that chemotherapeutics can provide several beneficial effects on the immune system, resulting in the improvement of the patient's prognosis (30).…”

Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study

“…The combination of chemotherapeutic agents, such as cisplatin, with ACT has been reported to improve the survival time of patients with cervical cancer (17). In the comparison between immune-cell therapy alone and immune-cell therapy combined with other treatments, several studies have demonstrated that combination therapy shows better therapeutic effects than immune-cell therapy alone (16,(18)(19)(20)(21). In our study, the combination of immune-cell therapy and chemotherapy did not provide any survival benefit for advanced or recurrent endometrial and cervical cancer patients, although the MST of these patients treated with a combination of immune-cell therapy and chemotherapy was longer than that of the historical control.…”

“…Adoptive immune-cell therapy is still under evaluation for use in advanced endometrial cancer, as in many other malignancies (16,20,21), but the more mature data available are about the checkpoint inhibitors. The PD-L1 expression levels in endometrial cancer have been estimated to be 67-100% (23).…”

Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix

“…Immune-cell therapy consists of adoptive T-cell therapy, DC vaccination, or their combination and is commonly administered six times at 2-week intervals for 3 months as one course. For adoptive T-cell therapy, activated lymphocytes were generated as previously described (14,15). In brief, peripheral blood mononuclear cells (PBMCs) were isolated from the patient's peripheral blood using a Vacutainer (Becton, Dickinson and Company, Franklin Lakes, NJ, USA).…”

“…The Seta Clinic Group, which includes four private clinics in Japan providing specialized types of immune-cell therapy in cooperation with cell-processing facilities, has treated a large number of patients with cancer over the past 10 years (11) and has investigated the effects of immune-cell therapy. It has reported some favorable results in some principal tumor types, including prolongation of survival time (12)(13)(14)(15)(16)(17)(18)(19). In our practice of immune-cell therapy for patients with gynecological malignancies, we have experience treating several patients with NECC who responded to immune-cell therapy markedly well.…”